GT Medical Technologies, a medical device company with a corporate purpose of improving the lives of patients with brain tumors, agreed to acquire radioactive seed assets from Perspective Therapeutics, a company manufacturing and distributing Cesium 131 brachytherapy radioisotope seeds. Financial terms were not disclosed. "By agreeing to acquire Cesium-131-related assets from Isoray, GT Medical Technologies is poised to enhance the delivery of GammaTile Therapy in the U.S. market, building on our commitment to excellence for both patients and the clinicians who treat them. Also, acquiring the legacy Isoray business will allow us to streamline existing operations and deepen our partnership with the radiation oncologist community. We are excited about integrating with Isoray's Cesium-131 brachytherapy team following the closing of the transaction," Matthew Likens, GT Medical Technologies CEO.